Catalyst Pharma Expects FY22 Revenue Beat Consensus On Continued Recovery In Macroeconomic, Healthcare Activity

Catalyst Pharmaceuticals Inc CPRX anticipates Q4 FY21 sales of approximately $38 million (consensus of $38.09 million), up roughly 24% Y/Y.

  • For FY21 total revenues are estimated to be approximately $141 million, an increase of roughly 18% Y/Y, better than the consensus of $138.3 million.
  • Last week, Catalyst announced that the District Court Judge in its case against the FDA had issued an order granting Catalyst Summary Judgment in its action against the FDA.
  • As a consequence of that order, the FDA has invalidated Jacobus Pharmaceutical Company Inc's Ruzurgi approval for pediatric patients with Lambert-Eaton myasthenic syndrome. 
  • The Company has ended the year with cash and investments of approximately $191 million, with no funded debt.
  • Guidance: The Company forecasts FY22 sales of $195 million - $205 million, representing a 38%-45% Y/Y increase, compared to the consensus of $163.53 million.
  • Price Action: CPRX shares are trading 6.04% at $5.97 during the market session on the last check Monday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: BiotechEarningsNewsGuidanceHealth CareSmall CapMoversTrading IdeasGeneralBriefswhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!